Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $1.4B | $1.3B | $693M | $532M | $321M | $258M | $188M | $62M |
| Beneficio bruto | $1.0B | $886M | $381M | $286M | $130M | $84M | $29M | $16M |
| % de margen bruto | 69.9% | 69.6% | 55.0% | 53.8% | 40.6% | 32.4% | 15.3% | 25.9% |
| Ingresos operativos (EBIT) | ($261M) | ($239M) | ($691M) | ($196M) | ($265M) | ($244M) | ($193M) | ($120M) |
| % de margen operativo | -18.2% | -18.8% | -99.7% | -36.9% | -82.8% | -94.5% | -102.9% | -193.0% |
| Ingresos netos | ($254M) | ($245M) | ($706M) | ($214M) | ($290M) | ($259M) | ($210M) | ($115M) |
| % de margen neto | -17.8% | -19.3% | -101.8% | -40.3% | -90.4% | -100.5% | -111.6% | -185.2% |
| EBITDA | — | ($222M) | ($610M) | ($133M) | ($237M) | ($220M) | ($169M) | ($100M) |
| Beneficio por acción (EPS) | $-1.44 | $-1.41 | $-4.35 | $-1.39 | $-1.71 | $-1.53 | $-1.24 | $-0.72 |
| Acciones en circulación (M) | — | 174M | 162M | 154M | 170M | 170M | 170M | 161M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de TEM. /companies/us/TEM
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms